Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE vs CARISOPRODOL AND ASPIRIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Orphenadrine citrate is a centrally acting muscle relaxant with anticholinergic properties; aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis; caffeine is a central nervous system stimulant that antagonizes adenosine receptors.
Carisoprodol is a centrally acting muscle relaxant that modulates GABA-A receptor activity and may act as a weak partial agonist at the central nervous system. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis, which results in analgesic, antipyretic, and anti-inflammatory effects.
Relief of discomfort associated with acute painful musculoskeletal conditions,Off-label: tension headache, migraine
Relief of discomfort associated with acute painful musculoskeletal conditions
1-2 tablets (orphenadrine citrate 50 mg, aspirin 770 mg, caffeine 60 mg per tablet) orally every 8-12 hours as needed; maximum 4 tablets per day.
1-2 tablets (carisoprodol 200 mg / aspirin 325 mg) orally 4 times daily.
Orphenadrine: ~14 hours (range 12-16 h); Aspirin: 2-3 h for low doses, 15-30 h for high/anti-inflammatory doses due to saturable metabolism; Caffeine: 3-6 h in adults, prolonged in liver disease.
Carisoprodol: 1.5-2 hours (terminal half-life), but active metabolite meprobamate has half-life of 9-12 hours, contributing to prolonged sedation. Aspirin: 15-20 minutes (parent drug); salicylate: 2-3 hours at low doses, 15-30 hours at high doses due to saturable hepatic metabolism.
Orphenadrine: hepatic N-demethylation and hydroxylation via CYP450 enzymes; Aspirin: hydrolysis to salicylate and conjugation with glycine and glucuronic acid; Caffeine: hepatic metabolism via CYP1A2.
Carisoprodol is N-deacetylated via CYP2C19 to meprobamate, a schedule IV controlled substance. Aspirin is hydrolyzed to salicylic acid in the liver and gastrointestinal tract.
Orphenadrine: ~60% renal (metabolites, <8% unchanged), ~20% biliary/fecal; Aspirin: ~80-100% renal (salicylates, dose-dependent; alkaline urine increases excretion); Caffeine: ~1-3% renal (unchanged), main metabolites renal.
Carisoprodol: Renal excretion of metabolites (hydroxycarisoprodol, meprobamate) and <1% unchanged. Aspirin: Renal excretion of salicylate and metabolites (salicyluric acid, gentisic acid); ~80% renal, with dose-dependent elimination via first-order and Michaelis-Menten kinetics.
Orphenadrine: ~30% (albumin); Aspirin: 80-90% (albumin, saturable); Caffeine: 25-36% (albumin).
Carisoprodol: ~60% bound to albumin. Aspirin: 80-90% bound to albumin (salicylate); highly protein-bound at therapeutic concentrations.
Orphenadrine: ~2.5 L/kg (widespread, CNS penetration); Aspirin: 0.15-0.2 L/kg (low, primarily extracellular); Caffeine: 0.6-0.8 L/kg.
Carisoprodol: ~0.7 L/kg (large Vd, extensive tissue distribution). Aspirin: ~0.15 L/kg (salicylate; low Vd, primarily in extracellular fluid). Clinical meaning: Carisoprodol distributes into CNS and muscle; aspirin remains largely in plasma and interstitial space.
Oral: Orphenadrine ~90%; Aspirin 40-50% (first-pass hydrolysis to salicylate); Caffeine ~100%.
Oral: Carisoprodol: ~90% (well absorbed). Aspirin: ~40-50% (presystemic hydrolysis in GI mucosa and liver; rectal: 100% absorbed, but avoids first-pass).
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For moderate impairment (Cr Cl 30-59 m L/min), extend dosing interval to every 12-24 hours. No adjustment for mild impairment (Cr Cl 60-89 m L/min).
e GFR 30-59 m L/min: avoid or reduce dose; e GFR <30 m L/min: contraindicated.
Contraindicated in Child-Pugh class C. For Child-Pugh class B, reduce dose by 50% or extend interval to every 12-24 hours. Use with caution in Child-Pugh class A.
Child-Pugh Class A: caution; Class B or C: contraindicated.
Not recommended for pediatric use due to aspirin's association with Reye's syndrome and lack of safety data for orphenadrine in children.
Not recommended for pediatric patients under 12 years of age. For older adolescents, weight-based dosing of aspirin 10-15 mg/kg/dose every 4-6 hours (max 80 mg/kg/day) and carisoprodol 5-10 mg/kg/dose three times daily; avoid routine use due to risk of Reye's syndrome.
Use lower end of dosing range (e.g., 1 tablet every 12 hours) due to increased sensitivity to anticholinergic effects and risk of aspirin-induced gastrointestinal bleeding. Avoid use in patients >80 years if possible.
Initiate at lowest effective dose; monitor for CNS depression, renal function, and bleeding risk. Avoid in patients with significant renal impairment or peptic ulcer disease.
No FDA black box warning.
None.
Avoid in patients with glaucoma, prostatic hypertrophy, or urinary retention due to anticholinergic effects; caution in elderly and those with cardiovascular disease; risk of GI bleeding with aspirin; limit caffeine intake to avoid excessive stimulation.
Dependence and withdrawal: Carisoprodol may cause dependence and withdrawal symptoms.,Sedation and CNS depression: Additive effects with alcohol and other CNS depressants.,Reye's syndrome: Aspirin use in children and teenagers with viral illness.,Gastrointestinal bleeding: Aspirin increases risk of GI bleeding.,Hypersensitivity reactions: Anaphylaxis, angioedema.
Hypersensitivity to any component; patients with angle-closure glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcer, prostatic hypertrophy, or bladder neck obstruction; severe renal or hepatic impairment; bleeding disorders; concurrent use of anticoagulants.
Hypersensitivity to carisoprodol or aspirin.,Children and teenagers with viral infections (Reye's syndrome risk).,Active peptic ulcer disease or GI bleeding.,Severe hepatic impairment.,History of asthma induced by aspirin or NSAIDs.,Concomitant use with meprobamate-containing products.
Avoid high-tyramine foods (e.g., aged cheeses, cured meats) due to orphenadrine's anticholinergic effects on gut motility. Evening meals high in caffeine may worsen insomnia. Aspirin absorption is delayed by food, but taking with food reduces GI irritation.
Avoid alcohol. Take with food or milk to reduce gastrointestinal irritation. Avoid high-tyramine foods (e.g., aged cheese, cured meats) as aspirin may potentiate tyramine effects.
First trimester: Aspirin is associated with increased risk of gastroschisis (ORS 1.5-2.0) and possibly cardiac defects; orphenadrine and caffeine have limited data but caffeine may increase miscarriage risk. Second trimester: Aspirin at high doses may impair fetal renal function; orphenadrine and caffeine effects are not well-studied. Third trimester: Aspirin use after 30 weeks gestation increases risk of premature closure of ductus arteriosus and oligohydramnios; orphenadrine may cause neonatal withdrawal; caffeine may accumulate.
First trimester: Aspirin associated with increased risk of neural tube defects and gastroschisis; carisoprodol limited data. Second and third trimesters: Aspirin use increases risk of premature closure of ductus arteriosus and oligohydramnios; carisoprodol not well studied but may cause neonatal withdrawal. Avoid in third trimester due to aspirin's antiprostaglandin effects.
Aspirin and its metabolites are excreted into breast milk (M/P ratio ~0.04-0.27 for salicylate); orphenadrine is not known to be excreted; caffeine is excreted (M/P ratio ~0.5-0.76). Theoretical risk of Reye's syndrome with aspirin, and irritability in infant with caffeine. Use caution, avoid high doses.
Aspirin and carisoprodol are excreted into breast milk. M/P ratio for aspirin is approximately 0.6-0.9; carisoprodol M/P ratio not established. Risk of Reye syndrome with aspirin, neonatal salicylate accumulation, and sedation from carisoprodol. Use not recommended during breastfeeding.
No specific pharmacokinetic studies for the combination; however, pregnancy increases renal clearance of aspirin, requiring dose adjustments for anti-inflammatory effect. Caffeine clearance decreases in later pregnancy; orphenadrine metabolism may be altered but data insufficient. Use lowest effective dose for shortest duration.
Pregnancy increases clearance of aspirin and carisoprodol; however, avoid use due to fetal risks. No recommended dose adjustments; contraindicated, especially in third trimester.
Orphenadrine citrate has anticholinergic properties; use cautiously in patients with glaucoma, urinary retention, or myasthenia gravis. Aspirin component increases bleeding risk, especially with concurrent anticoagulants. Caffeine may exacerbate anxiety or insomnia. Monitor for signs of salicylism with high doses or hepatic impairment.
Carisoprodol is metabolized to meprobamate, a controlled substance; monitor for abuse potential. Aspirin increases bleeding risk; avoid in children with viral illness due to Reye's syndrome. Combination may cause CNS depression and impaired motor function. Use with caution in renal impairment.
Take with food to reduce gastrointestinal upset.,Avoid alcohol while taking this medication.,Do not exceed recommended dosage; may cause dizziness or drowsiness.,Discontinue and seek medical attention if you experience signs of bleeding (e.g., black stools) or allergic reaction.,Inform your doctor if you have a history of stomach ulcers, bleeding disorders, or asthma.
Do not drive or operate machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants while taking this medication.,Take with food or milk to reduce stomach upset.,Do not use in children or teenagers with flu-like symptoms or chickenpox due to risk of Reye's syndrome.,Report signs of bleeding (easy bruising, black stools, vomiting blood) or allergic reactions (rash, swelling, difficulty breathing).,Rapid discontinuation may cause withdrawal symptoms (anxiety, insomnia, muscle twitching).
"Orphenadrine, a centrally acting muscle relaxant with sedative and anticholinergic properties, can potentiate the central nervous system (CNS) depressant effects of Ketazolam, a benzodiazepine anxiolytic. This synergistic pharmacodynamic interaction leads to enhanced sedation, impaired cognitive function, and increased risk of falls or respiratory depression, particularly in elderly or debilitated patients. The combination may also exacerbate anticholinergic side effects such as confusion and urinary retention."
"Orphenadrine, a centrally acting muscle relaxant with anticholinergic properties, may enhance the central nervous system depressant effects of lithium cation, an antimanic agent. This additive pharmacodynamic interaction can lead to increased sedation, dizziness, and confusion, potentially impairing cognitive and motor function. Clinically, patients may experience exacerbated lithium-induced neurotoxicity, manifesting as tremor, ataxia, or altered mental status, particularly in elderly or renally impaired individuals."
"Orphenadrine, a centrally acting muscle relaxant with anticholinergic properties, can potentiate the central nervous system (CNS) depressant effects of ethylmorphine, an opioid analgesic. This additive pharmacodynamic interaction may lead to enhanced sedation, respiratory depression, and psychomotor impairment, increasing the risk of falls, cognitive dysfunction, and potentially fatal respiratory compromise, particularly in elderly or debilitated patients."
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE vs CARISOPRODOL AND ASPIRIN, answered by our medical review team.
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE is a Skeletal Muscle Relaxant that works by Orphenadrine citrate is a centrally acting muscle relaxant with anticholinergic properties; aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis; caffeine is a central nervous system stimulant that antagonizes adenosine receptors.. CARISOPRODOL AND ASPIRIN is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting muscle relaxant that modulates GABA-A receptor activity and may act as a weak partial agonist at the central nervous system. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis, which results in analgesic, antipyretic, and anti-inflammatory effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE and CARISOPRODOL AND ASPIRIN depend on the specific clinical indication. These are both Skeletal Muscle Relaxant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE is: 1-2 tablets (orphenadrine citrate 50 mg, aspirin 770 mg, caffeine 60 mg per tablet) orally every 8-12 hours as needed; maximum 4 tablets per day.. The standard adult dose of CARISOPRODOL AND ASPIRIN is: 1-2 tablets (carisoprodol 200 mg / aspirin 325 mg) orally 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE and CARISOPRODOL AND ASPIRIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE is classified as Category A/B. First trimester: Aspirin is associated with increased risk of gastroschisis (ORS 1.5-2.0) and possibly cardiac defects; orphenadrine and caffeine have limited data but caffeine may. CARISOPRODOL AND ASPIRIN is classified as Category A/B. First trimester: Aspirin associated with increased risk of neural tube defects and gastroschisis; carisoprodol limited data. Second and third trimesters: Aspirin use increases risk. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.